{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:40:36Z","timestamp":1791405636519,"version":"4.3.3"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":549,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Human immunodeficiency virus (HIV)\/hepatitis C virus (HCV) coinfection is associated with progressive liver disease. However, the rate of progression is variable and the ability to differentiate patients with stable versus progressive HCV disease is limited. The objective of this study was to assess the incidence of and risk factors for fibrosis progression in a prospective cohort of coinfected patients. Overall, 435 liver biopsy pairs from 282 patients without cirrhosis were analyzed. Biopsies were scored according to the METAVIR system by a single pathologist blind to biopsy sequence. Fibrosis progression was defined as an increase of at least one METAVIR fibrosis stage between paired biopsies. The majority of patients were African American (84.8%), male (67.7%), and infected with HCV genotype 1 (93.4%). On initial biopsy, no or minimal fibrosis was identified in 243 patients (86%). The median interval between biopsies was 2.5 years. Fibrosis progression was observed in 97 of 282 (34%) patients and 149 of 435 (34%) biopsy pairs. After adjustment, greater body mass index (adjusted odds ratio [aOR]: 1.04 per 1 unit increase), diabetes (aOR: 1.56), and hepatic steatosis (aOR: 1.78) at the time of initial biopsy were marginally associated with subsequent fibrosis progression. Between biopsies, elevated serum aspartate and alanine aminotransferase (AST, ALT) (aOR AST: 3.34, ALT: 2.18 for &gt;25% values &gt;100 U\/L versus &lt;25% values &gt;100 U\/L) were strongly associated with fibrosis progression. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: Fibrosis progression is common among HIV\/HCV coinfected patients; these data suggest that progression can be rapid. Persistent elevations in serum transaminase levels may serve as important noninvasive markers to identify subsets of patients who are more likely to progress and thus warrant closer monitoring and consideration of HCV treatment. (HEPATOLOGY 2014;59:767\u2013775)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26741","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T23:48:19Z","timestamp":1381535299000},"page":"767-775","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":86,"title":["Fibrosis progression in human immunodeficiency virus\/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs"],"prefix":"10.1097","volume":"59","author":[{"given":"Monica A.","family":"Konerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti H.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine G.","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Torbenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20250207","doi-asserted-by":"crossref","first-page":"197207","DOI":"10.7326\/0003-4819-138-3-200302040-00012","article-title":"Hepatitis C in the HIVinfected person.","volume":"138","author":"Sulkowski","year":"2003","journal-title":"Ann Intern Med"},{"key":"R2-10-20250207","doi-asserted-by":"crossref","first-page":"831837","DOI":"10.1086\/339042","article-title":"Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a crosssectional analysis of the US adult AIDS Clinical Trials Group.","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R3-10-20250207","doi-asserted-by":"crossref","first-page":"22092216","DOI":"10.1097\/QAD.0b013e3282f10de9","article-title":"Rapid fibrosis progression among HIVhepatitis C viruscoinfected adults.","volume":"21","author":"Sulkowski","year":"2007","journal-title":"AIDS"},{"key":"R4-10-20250207","doi-asserted-by":"crossref","first-page":"18031809","DOI":"10.1097\/00002030-200308150-00009","article-title":"Mortality due to hepatitis Crelated liver disease in HIVinfected patients in France (Mortavic 2001 study).","volume":"17","author":"Rosenthal","year":"2003","journal-title":"AIDS"},{"key":"R5-10-20250207","doi-asserted-by":"crossref","first-page":"492497","DOI":"10.1086\/318501","article-title":"Increasing mortality due to endstage liver disease in patients with human immunodeficiency virus infection.","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R6-10-20250207","doi-asserted-by":"crossref","first-page":"283287","DOI":"10.1053\/jhep.2001.26517","article-title":"Factors affecting liver fibrosis in human immunodeficiency virusand hepatitis C viruscoinfected patients: impact of protease inhibitor therapy.","volume":"34","author":"Benhamou","year":"2001","journal-title":"Hepatology"},{"key":"R7-10-20250207","doi-asserted-by":"crossref","first-page":"10541058","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"R8-10-20250207","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1016\/j.jhep.2005.07.006","article-title":"Slower fibrosis progression in HIVHCVcoinfected patients with successful HIV suppression using antiretroviral therapy.","volume":"44","author":"Brau","year":"2006","journal-title":"J Hepatol"},{"key":"R9-10-20250207","doi-asserted-by":"crossref","first-page":"331337","DOI":"10.1111\/j.1468-1293.2006.00384.x","article-title":"Risk factors for fibrosis progression in HIVHCV coinfected patients from a retrospective analysis of liver biopsies in 19852002.","volume":"7","author":"Schiavini","year":"2006","journal-title":"HIV Med"},{"key":"R10-10-20250207","doi-asserted-by":"crossref","first-page":"10561063","DOI":"10.1002\/hep.23136","article-title":"Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virushepatitis C virus.","volume":"50","author":"Macias","year":"2009","journal-title":"Hepatology"},{"key":"R11-10-20250207","doi-asserted-by":"crossref","first-page":"615624","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIVcoinfected patients.","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"key":"R12-10-20250207","doi-asserted-by":"crossref","first-page":"23382354","DOI":"10.1111\/j.1572-0241.2005.00222.x","article-title":"Management and treatment of hepatitis C virus infection in HIVinfected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office.","volume":"100","author":"Tien","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R13-10-20250207","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00002030-200401020-00001","article-title":"Care of patients with hepatitis C and HIV coinfection.","volume":"18","author":"Soriano","year":"2004","journal-title":"AIDS"},{"key":"R14-10-20250207","doi-asserted-by":"crossref","first-page":"751753","DOI":"10.1097\/00002030-200303280-00015","article-title":"Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis?","volume":"17","author":"Soriano","year":"2003","journal-title":"AIDS"},{"key":"R15-10-20250207","doi-asserted-by":"crossref","first-page":"389402","DOI":"10.1080\/00365540902998271","article-title":"Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.","volume":"41","author":"Lagging","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"R16-10-20250207","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2893.2003.00491.x","article-title":"Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations.","volume":"11","author":"Soriano","year":"2004","journal-title":"J Viral Hepat"},{"key":"R17-10-20250207","first-page":"8495","article-title":"Which patients with hepatitis C virus should be treated?","volume":"11","author":"Shamoun","year":"2000","journal-title":"Semin Gastrointest Dis"},{"key":"R20-10-20250207","doi-asserted-by":"crossref","first-page":"24672474","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R21-10-20250207","doi-asserted-by":"crossref","first-page":"806811","DOI":"10.1111\/j.1365-2893.2007.00874.x","article-title":"Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count.","volume":"14","author":"Bonnard","year":"2007","journal-title":"J Viral Hepat"},{"key":"R22-10-20250207","first-page":"768774","article-title":"Progression of fibrosis in HIV and hepatitis C viruscoinfected patients treated with interferon plus ribavirinbased therapy: analysis of risk factors.","volume":"46","author":"BaniSadr","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R23-10-20250207","doi-asserted-by":"crossref","first-page":"464467","DOI":"10.1093\/alcalc\/agp039","article-title":"Preliminary evaluation of phosphatidylethanol and alcohol consumption in patients with liver disease and hypertension.","volume":"44","author":"Stewart","year":"2009","journal-title":"Alcohol Alcohol"},{"key":"R24-10-20250207","first-page":"1827","article-title":"The diagnostic value of combining carbohydratedeficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.","volume":"21","author":"ImbertBismut","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R25-10-20250207","doi-asserted-by":"crossref","first-page":"370378","DOI":"10.1001\/jama.2012.7844","article-title":"Relationship of liver disease stage and antiviral therapy with liverrelated events and death in adults coinfected with HIVHCV.","volume":"308","author":"Limketkai","year":"2012","journal-title":"JAMA"},{"key":"R26-10-20250207","doi-asserted-by":"crossref","first-page":"260274","DOI":"10.1016\/j.jana.2009.02.006","article-title":"HIV infection and obesity: a review of the evidence.","volume":"20","author":"Keithley","year":"2009","journal-title":"J Assoc Nurses AIDS Care"},{"key":"R27-10-20250207","doi-asserted-by":"crossref","first-page":"10261032","DOI":"10.1016\/j.jhep.2006.02.009","article-title":"Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection.","volume":"44","author":"Gaslightwala","year":"2006","journal-title":"J Hepatol"},{"key":"R28-10-20250207","doi-asserted-by":"crossref","first-page":"11181127","DOI":"10.1002\/hep.22134","article-title":"Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virushepatitis C virus coinfection.","volume":"47","author":"Sterling","year":"2008","journal-title":"Hepatology"},{"key":"R29-10-20250207","doi-asserted-by":"crossref","first-page":"19431949","DOI":"10.1086\/497608","article-title":"Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and Hepatitis C virus.","volume":"192","author":"Marks","year":"2005","journal-title":"J Infect Dis"},{"key":"R30-10-20250207","doi-asserted-by":"crossref","first-page":"585592","DOI":"10.1097\/01.aids.0000163935.99401.25","article-title":"Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus.","volume":"19","author":"Sulkowski","year":"2005","journal-title":"AIDS"},{"key":"R31-10-20250207","doi-asserted-by":"crossref","first-page":"307314","DOI":"10.1111\/j.1365-2893.2010.01417.x","article-title":"Winnock M, Lacombe K, Carrieri P, Neau D, Morlat P, et al. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIVHCVcoinfected patients.","volume":"18","author":"Loko","year":"2011","journal-title":"J Viral Hepat"},{"key":"R32-10-20250207","first-page":"109110","article-title":"Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIVHCVcoinfected patients.","volume":"1","author":"Ryan","year":"2009","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26741","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201403000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:03:41Z","timestamp":1738947821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201403000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26741","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}